• Alfa Wassermann SpA, of Bologna, Italy, and Norgine BV, of Amsterdam, the Netherlands, received European marketing authorization for Xifaxan 550-mg (rifaximin-alpha)/Refero/Targaxan/Tixteller for hepatic encephalopathy, a neuropsychiatric condition that can occur with cirrhosis of the liver. The drug will launch in Europe in the first half of 2013. It was registered in Australia in May 2012, and in the U.S. in March 2010.

• Dr. Reddy's Laboratories Ltd., of Hyderabad, India, acquired exclusive marketing and sales rights to Pamorelin LA (triptorelin) Depot, by Debiopharm Group, of Lausanne, Switzerland, in India for locally advanced or metastatic, hormone-dependent prostate cancer. Dr. Reddy's launched the product on Dec. 3, which is marketed in North America under the name Trelstar.